AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$BCYC

Lee Kevin sold $27K of BCYC

Lee Kevin (CHIEF EXECUTIVE OFFICER) sold 7,805 shares of BICYCLE THERAPEUTICS PLC (BCYC) at an average of $3.49 ($3.47–$3.57) across 2 trades over 2026-10-02 to 2026-10-05.

Original reporting
SEC EDGAR · Lee Kevin
Published Oct 6, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCYC
Neutral
medium confidence
Mentioned
$BCYC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCYCNeutralLow
01

Why it matters

The CEO's modest sale is unlikely to move the stock significantly but may attract short‑term attention.

02

Market read

A small insider sale with limited material impact; traders may monitor for any follow‑up activity.

03

What to watch

Potential upcoming clinical data releases could offset any short‑term pressure.

Relevance 3/10Novelty 3/10Timing: after filing today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$BCYCNeutralMedium confidence
Context

CEO Lee Kevin sold 7,805 shares for $27,247, reducing his stake to 595,866 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size is small relative to market cap and typical for a 10b5‑1 plan, but any CEO sale can prompt short‑term selling.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine and not indicative of future performance.

Key entities

  • Person
    Lee Kevin

    Chief Executive Officer of Bicycle Therapeutics PLC

  • Company
    Bicycle Therapeutics PLC

    Biotech company developing therapeutic candidates.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCYC insider trading history →

Related articles

OCT 29
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Bicycle Therapeutics (BCYC) reported Q3 2026 financial results and business updates. Nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer treatment. The company has $469.9M in cash, expecting runway into 2030. Clinical trials for nuzefatide and BT1702 are ongoing, with updates expected in 2027. Collaboration revenue increased to $34.1M, while R&D and G&A expenses decreased.

finanznachrichten.de6 min
OCT 29
$BCYCMed

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027 Initiation of the first company-sponsored

SEC EDGAR 8-K2 min
OCT 29
$BCYCMedAI 8/10

Bicycle Therapeutics reports Q3 results, FDA orphan status

Bicycle Therapeutics (BCYC) reported Q3 2026 results, with cash of $469.9M and collaboration revenue of $34.1M. The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer. The company expects its cash runway to extend into 2030 and plans to initiate a radioligand clinical trial for BT1702 in 2H 2027. Net loss was $10.5M, or $0.15 per share, compared to $59.1M, or $0.85 per share, in Q3 2025.

investing.com2 min
JUL 30
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).

finanznachrichten.de6 min
JUL 30
$BCYCMed

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology therapeutics with improved benefit/risk profiles co

SEC EDGAR 8-K6 min